You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5276 Results
Document
Mar 2023
Document
Mar 2023
Document
Mar 2023
Document
Mar 2023
Document
Mar 2023
The High Cost Therapy Funding Program primarily funds high-cost injectable or oral cancer drugs given in inpatient units of the hospital. The...
Document
Apr 2023
Document
Apr 2023
Le Programme de financement des traitements à coût élevé finance principalement les médicaments anticancéreux injectables ou oraux onéreux...
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOCEtaxel,
darolutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
darolutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024
Regimen
Cancer Type:
Endocrine, 
Thyroid
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
DOXOrubicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023

Pages